Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.12 (
PKG
)
2,515
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recently, the CLN3 gene associated with Batten disease (juvenile neuronal ceroid lipofuscinosis, JNCL), a recessively inherited, progressive, neurodegenerative disorder of childhood, has been identified. The CLN3 gene encodes a novel protein (battenin) of a predicted 438 amino acids containing several potential posttranslational modifications. We have expressed a full-length
CLN3 protein
as a C-terminal fusion with green fluorescent protein (GFP) to evaluate whether
CLN3 protein
is phosphorylated. By using in vivo labeling with 32P, detection with anti-phosphoamino acid antibodies, and phosphoamino acid analysis, we demonstrate that the
CLN3 protein
is phosphorylated on both serine and threonine residues. We also demonstrate that
CLN3 protein
is not modified by mannose 6-phosphate. Furthermore, we show that phosphorylation of
CLN3 protein
is carried out by protein kinase A (cAMP-dependent protein kinase, PKA), protein kinase G (
cGMP-dependent protein kinase
,
PKG
), and casein kinase II and that it is enhanced by inhibition of protein phosphatase 1 (PP 1) or protein phosphatase 2A (PP 2A).
...
PMID:Evidence for phosphorylation of CLN3 protein associated with Batten disease. 987 58